This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
17 Mar 2011

MorphoSys & Boehringer Sign Manufacturing Deal

MorphoSys AG and Boehringer Ingelheim will cooperate to work on the process development and manufacture of additional clinical material for MOR208 program.

MorphoSys AG and Boehringer Ingelheim have announced their manufacturing agreement for therapeutic antibodies. The deal covers the process development and manufacture of additional clinical material for MorphoSys’s MOR208 program and other drug candidates.
 
MOR208 is a potent monoclonal anti-CD19 antibody in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently in Phase I development in the U.S. by MorphoSys’s partner Xencor, Inc.
 
"Adding another supplier to our proprietary development set-up will help to prevent any bottlenecks in clinical trial supply in the years ahead,” said Dr. Marlies Sproll, chief scientific officer of Morpho

Related News